chitosan has been researched along with alpha-synuclein in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 3 (100.00) | 2.80 |
Authors | Studies |
---|---|
Alhakamy, NA; Anwer, MK; Bhattamisra, SK; Choudhury, H; Lim, WM; Md, S; Radhakrishnan, AK; Safian, NH; Shahzad, N; Shak, AT; Xi, LW | 1 |
Choudhury, SR; Karmakar, S; Sardoiwala, MN | 1 |
Lu, J; Qu, Y; Wang, B; Wang, L; Xia, W | 1 |
3 other study(ies) available for chitosan and alpha-synuclein
Article | Year |
---|---|
Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Blood-Brain Barrier; Cell Line, Tumor; Chitosan; Disease Models, Animal; Dopamine Agonists; Drug Carriers; Female; Haloperidol; Humans; Male; Nanoparticles; Neurons; Oxidopamine; Parkinson Disease, Secondary; Particle Size; Rats; Tetrahydronaphthalenes; Thiophenes; Toxicity Tests, Acute | 2020 |
Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
Topics: alpha-Synuclein; Animals; Biological Availability; Cell Line, Tumor; Chitosan; Disease Models, Animal; Drug Carriers; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Fingolimod Hydrochloride; Humans; Mice; Mice, Inbred BALB C; Neurons; Neuroprotective Agents; Parkinson Disease; Phosphorylation; Protein Aggregates; Protein Phosphatase 2; Proteolysis; Signal Transduction; Sphingosine 1 Phosphate Receptor Modulators; Ubiquitination | 2021 |
Chitosan oligosaccharides exert neuroprotective effects
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Chitosan; Disease Models, Animal; Humans; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Parkinson Disease; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2022 |